Superluminal Medicines raised an oversubscribed $60 million Series B to advance its pipeline of next-generation small-molecule therapies targeting challenging GPCRs in endocrine and cardiometabolic diseases. The company said the financing supports its move toward a first clinical study, combining AI/ML with protein dynamics and structural biology to drive discovery on GPCR targets that have been difficult to drug with conventional approaches.